Budget Impact Analysis of Anakinra (Kineret) in Treatment of Cryopyrin-Associated Periodic Syndromes in the Czech Republic

Cryopyrin-Associated Periodic Syndrome is a rare inherited disease caused by a defect in the patient's genetic resulting in constant overproduction of Interleukin-1beta which the body should normally produce only in response to infection. It manifests from birth or early childhood and persists throughout life. It occurs in three forms: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome and Chronic Infantile Neurologic Cutaneous Articular Syndrome or Neonatal Onset Multisystem Inflammatory Disease. Cost minimization analysis from the payers' perspective was performed to prove, that anakinra, an Interleukin-1 blocker, presents a cost-saving alternative compared to canakinumab. Results show, that anakinra would save 79.0 % of costs compared to canakinumab (Between 1.4 million CZK in the first year and 5.7 million CZK in the fifth year). Thus, making anakinra highly cost-saving alternative.